Animal models of cardiovascular disease for pharmacologic drug development and testing: Appropriateness of comparison to the human disease state and pharmacotherapeutics

American Journal of Therapeutics

Volumn 4, Issue 4, 1997, Pages 149-158

  Liao, Ronglih ^a   Carles, Maria ^b   Gwathmey, Judith K ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Calcium; Cardiomyopathy; Force frequency; Furazolidone; Heart; Myofilaments; Sarcoplasmic reticulum; Sympathetic nervous system; Turkey; receptors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; ASCORBIC ACID; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARTEOLOL; DIGITALIS; FURAZOLIDONE; INOTROPIC AGENT; METOPROLOL; NIFEDIPINE; PHENOXYBENZAMINE; PROPRANOLOL; VERAPAMIL;

ADRENERGIC SYSTEM; ANIMAL MODEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HISTOPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW;

EID: 0030912970     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199704000-00007     Document Type: Review

References (72)

1. Kannel WB: Epidemiologic aspects of heart failure. In Heart Failure: Current Concepts and Management. (Ed. Weber KT). Philadelphia: WB Saunders, 1989, pp 211-234.
2. Packer M: Survival in patients with chronic heat failure and its potential modification by drug therapy. Drug Treatment of Heart Failure (Ed. Cohn J). New Jersey: ATC International, 1988, pp. 273-290.
3. Kriett JM, Kaye MP: The Registry of the International Society for Heart Transplantation: Seventh Official Report. J Heart Transplant 1990;9:323-330.
4. Grattan MT, Moreno-Cabral CE, Starnes VA: Eight-year results of cyclosporine-treated patients with cardiac transplants. J Thorac Cardiovasc Surg 1990;99:500-511.
5. Gwathmey JK, Davidoff AJ: Experimental aspects of cardiomyopathy. Curr Opin Cardiol 1993;8:480-495.
6. Davidoff AJ, Gwathmey JK: Pathophysiology of cardiomyopathies. Part I: Animal models and humans. Curr Opin Cardiol 1994;9:357-368.
7. Gwathmey JK, Davidoff AJ: Pathophysiology of cardiomyopathies. Part II: Drug-induced and other interventions. Curr Opin Cardiol 1994;9:369-378.
8. Horackova M, Beresewicz A, Rowden G, Wilkinson M: Neurohormonal regulation of excitation contraction coupling in ventricular myocytes from cardiomyopathic hamsters. Cardiovasc Res 1991;25:1023-1034.
9. Kagiya T, Hori M, Iwakura K, et al.: Role of increased α1-adrenergic activity in cardiomyopathic syrian hamsters. Am J Physiol 1991;260:H80-88.
10. Anthony I, Chemla D, Lecarpentier Y: Myocardial contractility, lusitropy, and calcium responsiveness in young and hypertrophic cardiomyopathic hamsters. J Mol Cell Cardiol 1992;24:1089-1100.
11. Kuo TH, Tsang W, Wang KK, Carlock L: Simultaneous reduction of the sarcolemmal and SR calcium ATPase activities and gene expression in cardiomyopathic hamster. Biochim Biophys Acta 1992;1138:343-349.
12. Hajjar RJ, Liao R, Young JB, et al.: Pathophysiological and biochemical characterization of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. Cardiovasc Res 1993;27:2212-2221.
13. 2+ channel antagonists in an animal model of dilated cardiomyopathy: effects on gross morphology, global cardiac function, and twitch force. Circ Res 1993;73:1077-1089.
14. 2+ regulation with resultant implications on contractile performance. J Mol Cell Cardiol 1992;24:1459-1470.
15. Gwathmey JK: Morphological changes associated with furazolidone-induced cardiomyopathy: effects of digoxin and propranolol. J Comp Pathol 1991;104:33-45.
16. Gwathmey JK, Hamlin RL: Protection of turkeys against furazolidone-induced cardiomyopathy. Am J Cardiol 1983;52:626-628.
17. Gruver EJ, Glass MG, Marsh JD, and Gwathmey JK: An animal model of dilated cardiomyopathy: characterization of dihydropyridine receptors and contractile performance. Am J Physiol 1993;265(Heart Circ Physiol 34):H1704-H1711.
18. Gwathmey JK: Furazolidone-induced cardiomyopathy in turkey poults. In Pathogenesis of Myocarditis and Cardiomyopathy. (Eds. Kawai C, Matsumori A, Abelmann H), Tokyo: Tokyo University Press, 1988, pp. 107-120.
19. Conrad CH, Brooks WW, Robinson KG, Bing OHL: Impaired myocardial function in spontaneously hypertensive rats with heart failure. Am J Physiol 1991;260:H136-H145.
20. Gwathmey JK: Experimental cardiomyopathies. In Atlas of Heart Diseases, (Ed. E Braunwald), pp. 11.0-11.21.
21. Francis GS: Neuroendocrine manifestations of congestive heart failure. Am J Cardiol 1988;62:9-17.
22. Cohn JN, Levine T, Olivari MT: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1994;311:822-830.
23. Bristow MR, Hershberger RE, Port JD: β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990;82:12-21.
24. 2 receptor density. Circulation 1994;90:I-212 (abstract).
25. 2 receptors. 1980;17:1-7.
26. Marsh JD, Smith TW: Receptors for beta adrenergic agonists in cultured chick ventricular cells. Relationship between agonist effect and physiologic binding. Mol Pharmacol 1985;27:10-18.
27. Aurbach GD, Spiegel AM, Gardner JD: β-Adrenergic receptors, cyclic AMP and ion transport in avian erythrocyte. In Advances in Cyclic Nucleotide Research. (Eds Drummond GI, Greengard P, Robison GA) New York: Raven Press 1975, pp. 132-143.
28. Oye I, Sutherland EW: The effect of epinephrine and other agents on adenyl cyclase of cell membrane of avian erythrocytes. Biochem Biophys Acta 1966;127:347-354.
29. 2+ and force regulation. Basic Res Cardiol 1992;87:143-159.
30. 2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988;82:1578-1584.
31. 2+. Circulation 1990;82:1266-1278.
32. Pagani ED, Alousi AA, Grant AM, Allen PD: Changes myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 1988;63:380-385.
33. Rouleau JL, Chuck LH, Hollosi G, et al.: Verapamil preserves myocardial contractility in the hereditary cardiomyopathy of the Syrian hamster. Circ Res 1982;50(3):405-412.
34. Finkel MS, Shen L, Oddis CV, Romeo RC: Verapamil regulation of a defective SR release channel in the cardiomyopathic Syrian hamster. Life Sci 1993;52:1109-1119.
35. Finkel Ms, Shen L, Oddis CV, Salama G: Inotropic effects of calcium antagonists in the cardiomyopathic Syrian hamster. J Cardiovasc Pharmacol 1992;19:546-553.
36. Waagstein F, Hjalmarson A: Use of beta-blockers in the treatment of dilated cardiomyopathy. In Heart Failure: Basic Science and Clinical Aspects. (Eds. Gwathmey JK, Briggs GM, Allen PD) New York Marcel Dekker, 1993, pp. 235-253.
37. Jasmin G, Bajusz E: Selective prevention by verapamil and other drugs of the hamster hereditary cardiomyopathy. In Recent Advances in Myology. Eds. Bradley WS, Gardner D, Medum D, Walton J. New York, Elsevier, 1975, pp 413-417.
38. Gwathmey JK, Copelas L, MacKinnon R et al.: Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
39. Gwathmey JK, Slawsky MT, Hajjar RJ, et al.: Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J Clin Invest 1990;85:1599-1613.
40. Beuckelmann DJ, Nabauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
41. Vahl CF, Bonz A, Timek T, Hagl S: Intracellular calcium transient of working human myocardium of seven patients transplanted for congestive heart failure. Circ Res 1994;74:952-958.
42. Arai M, Alpert NR, Mac Lennan DH, et al.: Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-469.
43. Gwathmey JK, Liao R, Hajjar RJ: Intracellular free calcium in hypertrophy and failure. In Diastolic Relaxation of the Heart. (Eds. Lorell BH, Grossman W) Norwell, MA: Kluwer Academic Publishers, 1994, pp. 54-64.
44. 2+ and ATP-cycling imbalances in end-stage idiopathic dilated and ischemic cardiomyopathies. Cardiovasc Res 1995;30:394-404.
45. Gwathmey Jk, Morgan JP: Altered calcium handling in experimental pressure-overload hypertrophy in the ferret. Circ Res 1985;57:836-843.
46. Gwathmey JK, Morgan JP: Sarcoplasmic reticulum calcium mobilization in right ventricular pressure-overload hypertrophy in the ferret: relationships to diastolic dysfunction and a negative treppe. Pfluegers Arch 1993;422:599-608.
47. Gwathmey JK, Liao R, Ingwall JS: Comparison of twitch force and calcium handling in papillary muscles from right ventricular pressure overload hypertrophy in weanling and juvenile ferrets. Cardiovasc Res 1995;29:475-481.
48. 2+ in aortic banded rats. Circulation 1996.
49. Bowditch HP: Ueber die Eigenthuemhlichkeiten der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Ber Saechs Ges (Akad) Wiss 1871;23:652-689.
50. Buckley NM, Penefsky ZJ, Litwak RS: Comparative force-frequency relationships in human and other mammalian ventricular myocardium. Pflugers Arch Ges Physiol Menschen Tiere 1972;332:259-270.
51. Feldman MD, Alderman JD, Aroesty JM, et al.: Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 1988;82:1661-1669.
52. Feldman MD, Gwathmey JK, Phillips P, et al.: Reversal of the force frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 1988;3:273-283.
53. Mulieri LA, Hasenfuss G, Leavitt B, et al.: Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-1750.
54. Schwinger RHG, Bohm M, Mueller-Ehmsen J, et al.: Effect of inotropic stimulation on the negative force frequency relationship in the failing human heart. Circulation 1993;88:2267-2276.
55. Phillips PJ, Gwathmey JK, Feldman MD, et al.: Post-extrasystolic potentiation and the force-frequency relationship: Differential augmentation of myocardial contractility in working myocardium from patients with end-stage heart failure. J Mol Cell Cardiol 1990;22:99-110.
56. Schmidt U, Hajjar RJ, Gwathmey JK: Force-Interval relationship in human myocardium. J Cardiac Failure 1995;1(4):311-321.
57. Brooks WL, Bing OHL, Litwin SE, et al.: Effects of treppe and calcium on intracellular calcium and function in the failing heart from the spontaneously hypertensive rat. Hypertension 1994;24:347-356.
58. Eising GP, Hammond HK, Helmer GA, et al.: Force-frequency relations during heart failure in pigs. Am J Physiol 1994;267:H2516-H2522.
59. Zue MR, Mukherjee R, Clayton C, et al.: Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol 1994;267:H556-565.
60. Ingwall JS, Nascimben L, Gwathmey JK: Heart failure: Is the pathology due to calcium overload or to mismatch in energy supply and demand. In Heart Failure: Basic Research and Clinical Aspects.(Eds Gwathmey JK, Briggs GM, Allen PD). New York: Marcel Dekker, 1993, pp. 667-700.
61. Gwathmey JK, Ingwall JS: Mechanisms responsible for altered calcium homeostasis during congestive heart failure. Cardiol Rev 1995;3:282-291.
62. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992;86:1810-1818.
63. Liao R, Nascimben L, Friedrich J, et al.: Decreased energy reserve in an animal model of dilated cardiomyopathy: relationship to contractile performance. Circ Res 1996;78:893-902.
64. Nascimben L, Friedrich J, Liao R, et al.: ACE inhibitor treatment increases creatine kinase reaction velocity in failing myocardium of Syrian myopathic hamsters. Circulation 1995;91:1824-1833.
65. Neubauer S, Horn M, Naumann A, et al.: Impairment of energy metabolism in intact residual myocardium of rat hearts with chromic myocardial infarction. J Clin Invest 1995;95:1092-1100.
66. Fuleihan F, Matsumori A, Gwathmey JK: Effects of carteolol a β-blocker, on mortality and left ventricular heart function in dilated cardiomyopathy. Circulation 1993;88(Suppl)I-192.
67. Gelbfish JS, Slawsky MT, Fried GW, Gwathmey JK: β-Blockade induced resolution of dilated cardiomyopathy in an experimental model [abstract]. Circulation 1990;82:291.
68. Gelbfish JS, Slawsky MT, Gwathmey JK: Beta-blockade induced resolution of dilated cardiomyopathy [abstract]. Circulation 1989;80:II-675.
69. Glass MG, Reis I, O'Brien PJ, et al.: Reversal of the negative treppe with β-blockers: role of the sarcoplasmic reticulum function and myocardial energetics [abstract]. Circulation 1993;88:526.
70. 2 receptor density [abstract]. Circulation 1994;90:212.
71. Gwathmey JK: The effects of digitalis or propranolol on furazolidone-induced cardiomyopathy. Dissertation, Ohio State University, 1983.
72. Chapados RA, Gruver EJ, Ingwall JS, et al.: Chronic administration of cardiovascular drugs: Altered energetics and transmembrane signalling. Am J Physiol 1992;263: H1576-1586.